Recent Report on Multiple Sclerosis - Pipeline Review, H1 2016

Multiple Sclerosis - Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Multiple Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development,mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report with TOC available @ ​Multiple Sclerosis - Pipeline Review, H1 2016.

Scope

- The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis
- The report reviews pipeline therapeutics for Multiple Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Multiple Sclerosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Companies Mentioned

4D Pharma Plc 4SC AG AB Science SA AbbVie Inc. Ablynx NV Acorda Therapeutics, Inc. Actelion Ltd Addex Therapeutics Ltd Adhaere Pharmaceuticals, Inc. Aegis Therapeutics, LLC Affectis Pharmaceuticals AG AiCuris GmbH & Co. KG Alkermes Plc Alpha Cancer Technologies Inc. Amarna Therapeutics B.V. Anavex Life Sciences Corp. Antisense Therapeutics Limited Antitope Limited Aphios Corporation Apitope International NV Arena Pharmaceuticals, Inc. Argos Therapeutics, Inc. Arrien Pharmaceuticals, LLC Artielle ImmunoTherapeutics, Inc. Astellas Pharma Inc. Asterias Biotherapeutics, Inc. Atara Biotherapeutics, Inc. Athersys, Inc. Axxam SpA Baliopharm AG Bio-Cancer Treatment International Limited BioAegis Therapeutics, Inc. etc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###